V
Virginia L. Kan
Researcher at George Washington University
Publications - 46
Citations - 1265
Virginia L. Kan is an academic researcher from George Washington University. The author has contributed to research in topics: Viral load & Veterans Affairs. The author has an hindex of 15, co-authored 46 publications receiving 1165 citations. Previous affiliations of Virginia L. Kan include Washington University in St. Louis & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
The Effect of Statins on Mortality in Patients with Bacteremia
TL;DR: A potential clinical role of statins in bacteremic infection is suggested; however, the mechanism by which mortality is reduced remains undefined.
Journal ArticleDOI
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
J D Lundgren,Birgit Grund,Christina E. Barkauskas,Thomas L. Holland,Robert L. Gottlieb,Uriel Sandkovsky,Samuel M. Brown,Kirk U. Knowlton,Wesley H. Self,D. Clark Files,Mamta K Jain,T. Benfield,Michael E Bowdish,Bradley G Leshnower,Jason V. Baker,Jens-Ulrik Stæhr Jensen,Edward M. Gardner,Adit A. Ginde,Estelle S. Harris,Isik Somuncu Johansen,Norman Markowitz,Michael A. Matthay,Lars Østergaard,Christina C. Chang,Victoria J. Davey,Anna L. Goodman,Elizabeth S. Higgs,Elizabeth S. Higgs,Daniel D Murray,Thomas A. Murray,Roger Paredes,Mahesh K. B. Parmar,Andrew N. Phillips,Cavan S. Reilly,Shweta Sharma,Robin L. Dewar,Marc Teitelbaum,Deborah Wentworth,Huyen Cao,Paul Klekotka,Abdel Babiker,Annetine C. Gelijns,Virginia L. Kan,Virginia L. Kan,Mark N. Polizzotto,Mark N. Polizzotto,B. Taylor Thompson,H. Clifford Lane,James D. Neaton +48 more
TL;DR: In this paper, the effect of neutralizing monoclonal antibody (YL-CoV555) on patients with Coronavirus disease 2019 (Covid-19) was investigated.
Journal ArticleDOI
Polymerase Chain Reaction for the Diagnosis of Candidemia
TL;DR: A PCR assay was developed for the diagnosis of candidemia that detected Circulating Candida DNA from plasma of mice with induced candidemia and from sera in 11 (79%) of 14 patients with blood cultures positive for Candida species.
Journal ArticleDOI
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Richard T. Davey,Eduardo Fernández-Cruz,Norman Markowitz,Sarah Pett,Abdel Babiker,Deborah Wentworth,Surender Khurana,Nicole Engen,Fred M. Gordin,Mamta K. Jain,Virginia L. Kan,Mark N. Polizzotto,Paul F. Riska,Kiat Ruxrungtham,Zelalem Temesgen,Jens D Lundgren,John H. Beigel,H. Clifford Lane,James D. Neaton,Jessica Butts,Eileen Denning,Alain DuChene,Eric A. Krum,Merrie Harrison,Sue Meger,Ross L. Peterson,Kien Quan,Megan Shaughnessy,Greg Thompson,David M. Vock,Julia A. Metcalf,Robin Dewar,Tauseef Rehman,Ven Natarajan,Rose McConnell,Emily Flowers,Kenny Smith,Marie Hoover,Elizabeth M Coyle,David Munroe,Bitten Aagaard,Mary Pearson,Adam Cursley,Helen Webb,Fleur Hudson,Charlotte Russell,Aminata Sy,Cara Purvis,Brooke Jackson,Yolanda Collaco-Moraes,Dianne Carey,Rosemary Robson,Adriana Sánchez,Elizabeth Finley,Donna Conwell,Marcelo H. Losso,Luciana Gambardella,Cecilia Abela,Paco Lopez,Helena Alonso,Giota Touloumi,Vicky Gioukari,Olga Anagnostou,Anchalee Avihingsanon,Kanitta Pussadee,Sasiwimol Ubolyam,Bola Omotosho,Clemencia Solórzano,Tianna Petersen,Kranthi Vysyaraju,Stacey A Rizza,Jennifer A Whitaker,Raquel Nahra,John D. Baxter,Patricia Coburn,Edward M. Gardner,James A Scott,Leslie Faber,Erica Pastor,Linda Makohon,Rodger A MacArthur,L Monique Hillman,Marti J Farrough,Hari M Polenakovik,Linda A Clark,Roberto J Colon,Ken M. Kunisaki,Miranda DeConcini,Susan A Johnson,Cameron R. Wolfe,Laura Mkumba,June Y Carbonneau,Alison Morris,Meghan Fitzpatrick,Cathy J Kessinger,Robert A. Salata,Karen A Arters,Catherine M Tasi,Ralph J. Panos,Laura A Lach,Marshall J. Glesby,Kirsis Ham,Valery G Hughes,Robert T. Schooley,Daniel Crouch,Leticia Muttera,Richard M. Novak,Susan C Bleasdale,Ariel E Zuckerman,Weerawat Manosuthi,Supeda Thaonyen,Thaniya Chiewcharn,Gompol Suwanpimolkul,Sivaporn Gatechumpol,Sirikunya Bunpasang,Brian Angus,Monique Anderson,Marcus Morgan,Jane Minton,Maria N Gkamaletsou,Joe Hambleton,David Price,Martin J Llewelyn,Jonathan Sweetman,Javier Carbone,Jose R. Arribas,Rocio Montejano,Jose L Lobo Beristain,Iñaki Z Martinez,Jose Barberan,Paola Hernandez,Dominic E. Dwyer,Jen Kok,Álvaro H. Borges,Christian Brandt,Lene S Knudsen,Nikolaos Sypsas,Costas S. Constantinou,Antonios Markogiannakis,Spyros Zakynthinos,Paraskevi Katsaounou,Ioannis Kalomenidis,Analia Mykietiuk,Maria F Alzogaray,Mora Obed,Laura Moreno Macias,Juan Ebensrtejin,Patricia Burgoa,Esteban C. Nannini,Matias Lahitte,Santiago Perez-Patrigeon,José Arturo Martínez-Orozco,Juan Pablo Ramírez-Hinojosa +152 more
TL;DR: In this article, the authors evaluated the safety and efficacy of intravenous immunoglobulin (HIVIG) in a randomized controlled trial. But, they did not evaluate the effect of the infusion of high-titre hIVIG on clinical outcomes.
Journal ArticleDOI
Is Frequent CD4+ T-Lymphocyte Count Monitoring Necessary for Persons With Counts ≥300 Cells/µL and HIV-1 Suppression?
Howard B. Gale,Steven R. Gitterman,Heather J. Hoffman,Fred M. Gordin,Fred M. Gordin,Debra Benator,Debra Benator,Ann M. Labriola,Ann M. Labriola,Virginia L. Kan,Virginia L. Kan +10 more
TL;DR: The authors' data support less frequent CD4 monitoring during viral suppression, and suggest that among patients infected with human immunodeficiency virus (HIV), those with HIV-1 RNA <200 copies/mL and CD4 counts ≥300 cells/µL had a 97.1% probability of maintaining durable CD4 for 4 years.